Search Results

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics.

Business

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.

April 25, 2024

·

10 min read

Press Releases

Mammoth Biosciences to Present Preclinical Data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress

October 1, 2025

·

3 min read

Business

Jennifer Doudna’s Mammoth Links with Vertex in $700 Million Ultra-Small CRISPR Deal

Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.

October 26, 2021

·

4 min read

·

Gail Dutton

Press Releases

Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors

May 5, 2025

·

4 min read

Press Releases

Mammoth Biosciences to Present Preclinical Data on In Vivo Gene Editing of Skeletal Muscle in Non-Human Primates with an Ultracompact CRISPR System at ASGCT 2025

May 1, 2025

·

2 min read

Press Releases

Mammoth Biosciences Announces New Results on NanoCas – the First Efficient Ultracompact Extrahepatic Gene Editor

January 31, 2025

·

4 min read

Press Releases

Mammoth Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8, 2025

·

1 min read

Biotech Bay

Mammoth Biosciences Raises $45 Million to Build Next Generation CRISPR Products For Therapeutics and Diagnostics

Already the leader in CRISPR-based disease detection, the latest round will drive Mammoth’s robust platform for protein discovery to extend into gene-editing and therapeutics applications.

February 5, 2020

·

4 min read

Biotech Bay

Mammoth Biosciences to Present at Annual Meeting of the American Society of Gene & Cell Therapy

Mammoth Biosciences today announced that Lucas Harrington, Ph.D., Mammoth’s co-founder and Chief Scientific Officer, will present new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, May 7 - 11, 2024.

May 2, 2024

·

3 min read